Celon Pharma 2025: record PLN 244m revenue, but the net loss deepens to PLN 79.4m – the 2026 outlook hinges on Salmex in China and the GLP-1 programme

Celon Pharma 2025: revenue of PLN 244m (+17.9%), but the net loss deepens to PLN 79.4m – the cost of the GLP-1 programme

Celon Pharma S.A. – headquartered at ul. Ogrodowa 2A in Kiełpin (Łomianki municipality, Mazowieckie voivodeship, postcode 05-092) and registered in the KRS under number 0000437778 – closed 2025 with consolidated revenue of PLN 244.34m (+17.9% YoY, up from PLN 207.19m in 2024) and EBITDA of PLN 21.42m (+42% from PLN 15.05m). The operating result is positive, but the net loss deepened to PLN 79.36m from PLN 34.45m a year earlier. That is the direct effect of spending on the new flagship R&D programme – GLP-1 receptor agonists in cardiometabolic disease – which is meant to become the main earnings driver in 2026–2028 but absorbs capital and widens the gap between reported EBITDA and the bottom line.

The structural divergence between the company's two businesses matters for interpretation. The generics segment (lead products: the Salmex inhaler and cardiology drug Zarixa) generates 84.4% of revenue – PLN 206.25m, up 15.3% YoY. Exports from that segment exceeded PLN 44m (versus PLN 41.6m). The innovation segment (R&D, grants, clinical programmes) accounts for 15.6% of revenue (PLN 38.09m, +34.3% YoY), with grant revenue rising from PLN 28.3m to PLN 38.3m. The generic core remains a strong cash generator, but its margin does not cover the scale of GLP-1 pipeline spending.

In the background: Celon Pharma's Chinese partner is holding to a Salmex registration timeline of end-2026. If it succeeds, Salmex becomes the main export lever; if registration slips, the expected 2026–2027 export growth has to be pushed out. Q1 2025 already gave a clear signal – company exports grew 73% YoY to PLN 13.8m.

Celon Pharma

KIEŁPIN · KRS 0000437778 · SPÓŁKA AKCYJNA

Revenue

244.3 M PLN

Kiełpin (Łomianki), Ogrodowa 2A: Wieczorek's two-member board, founder control of 58.8% of capital and 68.2% of votes

The address ul. Ogrodowa 2A in Kiełpin – a village in the Łomianki municipality west of Warsaw – places Celon Pharma's seat in the suburban Warsaw pharmaceutical cluster of the Warszawa-zachodni district. The company has operated in its current corporate form (Celon Pharma S.A., KRS 0000437778) since 25 October 2012 (previously as a limited-liability company) and has been listed on the Warsaw Stock Exchange since 2016. It belongs to the sWIG80 index.

Governance: a two-member management board – CEO Maciej Wieczorek (the founder) plus one board member. The cap table is heavily founder-concentrated: through Glatton sp. z o.o. (which he wholly owns), Wieczorek controls 58.8% of the capital and 68.2% of voting rights at the AGM (as of January 2024). That makes Celon Pharma effectively family-controlled despite its formal WSE listing. The remaining shares are held by pension and investment funds – free float is around 41%.

Under Polish PKD codes the principal activity is 21.20.Z (manufacture of pharmaceutical preparations). The company has a registered electronic-delivery address (AE:PL-58206-76240-RVIES-16), the e-mail info@celonpharma.com and the website celonpharma.com.

A significant corporate event is under way: the formal separation of the generics and innovation businesses into distinct companies. The operation is due to complete in 2026 and aims to separate the predictable generics segment (Salmex and other reimbursed drugs) from the capital-intensive innovation segment (R&D in GLP-1, FGFR and oncology). No share issue is planned for 2026 – pipeline funding is to come from current sales and grants.

The Polish pharma sector on the WSE: Celon Pharma as the only hybrid "generics plus R&D" player

The Polish pharmaceutical sector listed in Warsaw has a distinctive structure in 2026:

• Celon Pharma (Kiełpin) – hybrid: 84% generics, 16% innovation; deepening R&D investment in GLP-1.
• Bioton (Warsaw) – a pure biosynthetic-insulin manufacturer, revenue-generating but still loss-making; controlled by China's Yifan.
• Mabion (Konstantynów Łódzki, mWIG40) – a contract biotech with the Novavax CDMO agreement; lower risk than Celon or Bioton.
• Ryvu Therapeutics (Kraków, mWIG40) – a pre-commercial oncology biotech (RVU120 in Phase II) with no drug-sales revenue.
• Bioceltix (Wrocław) – a pre-commercial veterinary biotech.
• Selvita – a contract research organisation, revenue-generating.

Three structural features of the Celon Pharma model explain the divergence between rising revenue and the deeper loss:

• The hybrid "generics plus innovation" model is a rarity in Polish pharma – most Polish pharmaceutical companies are either purely generic (Polpharma, Aflofarm, both unlisted) or purely pre-commercial (Ryvu, Captor, Bioceltix). Celon is attempting a Genmab-style strategy, with generics funding the R&D pipeline. It works in Scandinavian and German pharma, but requires a generics business much larger than the current PLN 244m a year.
• GLP-1 as the 2026 priority and an execution risk – GLP-1 receptor agonists (the class including semaglutide and tirzepatide, the global hits from Novo Nordisk and Eli Lilly) are currently the most lucrative segment of global pharma, with sales above USD 100bn a year and projections above USD 200bn by 2030. Celon Pharma is developing its own GLP-1 agonists for the European and Middle Eastern markets, with the option of producing an oral form at its Slovak plant. The risk: competition from giants whose R&D budgets are a hundred times larger than a Polish biotech's. Time to market is the critical competitive factor.
• Salmex in China as a single high-risk 2026 catalyst – Salmex registration in China is a multi-year partnership process, and the partner's end-2026 timeline guarantees nothing. A favourable decision by the Chinese regulator (NMPA) would open a market worth billions of euros a year; a negative decision or a delay keeps export growth at moderate levels.

What this means for the investment profile: a deeper loss by design, no dividend, dependence on the pipeline

The interpretation is speculative – the conclusions below are scenarios, not certainties:

“The Group is consistently developing innovative therapies with global potential while strengthening the generics business - particularly in the cardiometabolic area.”

Three possible consequences of the 2025 results for Celon Pharma's investment profile in 2026:

• The deeper net loss is deliberate spending, not operating deterioration – EBITDA growth of 42% shows the underlying generics business is improving operationally. The wider net loss is driven mainly by GLP-1 pipeline spending, clinical programmes and depreciation. An investor treating Celon as a pre-commercial company (as with Ryvu) should focus on EBITDA and pipeline progress rather than the bottom line. Conversely, an investor looking for dividend pharma should rotate – the loss rules out a 2026 payout.
• Salmex in China as a binary event for 2026 – registration expected by the end of 2026 is a single high-risk catalyst. A positive NMPA decision could double Celon Pharma's exports in 2027. A negative decision or delay would leave the current export momentum from other markets intact, but without Chinese scale.
• GLP-1 means a five-to-seven-year horizon and heavy capital intensity – full development of a GLP-1 clinical line (Phase I through III to registration) typically takes five to seven years from the strategic decision. Exposure to this segment is positioned for 2030 and beyond – leverage for the patient investor, not for the 2026 results cycle.

Main company-specific risks over the 2026–2027 cycle:

• The deepened net loss – accumulated losses preclude a dividend for several years; no share issue is planned for 2026, but one is possible if capital needs arise.
• Salmex registration in China – a single high-risk catalyst on an unguaranteed timeline.
• GLP-1 competition from Novo Nordisk and Eli Lilly – global giants with R&D budgets a hundred times larger.
• Wieczorek's control (58.8% of capital, 68.2% of votes) – low free-float liquidity; strategic decisions rest with one founder-shareholder.
• The separation of the businesses into distinct companies – under way in 2026, and liable to affect the capital structure and market perception.

What you'll find in the Celon Pharma S.A. profile

The Celon Pharma S.A. profile in our database carries the full picture of the company: the composition of the two-member management board (with founder-CEO Maciej Wieczorek), the KRS registration history since 25 October 2012, the registered address at ul. Ogrodowa 2A in Kiełpin, e-delivery status (AE:PL-58206-76240-RVIES-16), the website celonpharma.com, the e-mail info@celonpharma.com, and the assigned PKD code 21.20.Z (manufacture of pharmaceuticals). The profile is also available in English – relevant for international biotech and pharma fund investors, since Celon Pharma is the only listed Polish hybrid "generics plus innovation" player, with an active GLP-1 pipeline and a potential Salmex registration in China.

This material is for information purposes only and does not constitute investment advice.

Data: Polish KRS Court Register (KRS 0000437778); Celon Pharma S.A. – consolidated annual report RR/2025; financial statements filed with KRS; Stockwatch – analysis of Celon Pharma's 2025 results; Inwestycje.pl – report on Celon Pharma's 2025 net loss and EBITDA; pl.investing.com / ISBnews – reports on Salmex registration in China and Q1 2025 exports; Stockwatch – analysis of Celon Pharma's 2026 exports and new markets (the Gulf, Mexico, South Africa); Bankier ESPI – RR/2025 current report; Rejestr.io – shareholder structure and Glatton sp. z o.o. control; PKD 21.20.Z classification (manufacture of pharmaceuticals); company history – incorporated 25 October 2012 as an S.A., WSE debut 2016, as of 2026-07-27.